Anand Kumar, Ray Subhabrata, Rahman Mahfoozur, Shaharyar Adil, Bhowmik Rudranil, Bera Rammohan, Karmakar Sanmoy
Department of Pharmaceutical Technology, Jadavpur University, Kolkata-700032, West Bengal, India.
Dr. B.C. Roy College of Pharmacy & Allied Health Sciences, Durgapur, West 713206 Bengal, India.
Recent Pat Antiinfect Drug Discov. 2019;14(1):16-35. doi: 10.2174/1574891X14666190717111531.
In recent decades, enormous efforts for different drug discovery processes have led to a number of drug molecules available today to overcome different challenges of the health care system. Unfortunately, more than half of these drugs are listed in either BCS (biopharmaceutical classification system) class II/ IV or both are eliminated from the development pipeline due to their limited clinical use. A nanotechnological approach bears much hope and lipoidal fabrication is found to be suitable for the delivery of such drugs. Nanoemulsion based gel i.e. nanoemulgel out of different nanolipoidal formulations has been found to be a suitable approach to successful drug delivery through topical routes. In past few years many herbal and synthetic active pharmaceutical ingredients (APIs) has been patented as nano sized emulsified gel for various therapeutic activities.
Nanoemulgel is basically an emulsion-based topical gel formulation, where nanosized emulsion globules can be prepared with the help of high energy or low energy methods and further converted into nanoemulgel by adding a suitable gelling agent. Nanoemulgel fabrication enlists various kinds of polymeric materials, surfactants and fatty substances of natural, synthetic and semi-synthetic nature with a globule size range from 5 to 500 nm.
Nanoemulgel can be applicable to various acute and chronic diseases through topical routes.
Nanoemulgel preparations of many recently approved drugs are being used successfully in different areas of health care and have re-defined the significance of topical route of delivery as compared to other routes. However, along with various improvements in the current state of the delivery system, the safety factor needs to be taken into account by toxicological studies of the materials used in such formulations.
近几十年来,为不同的药物发现过程付出了巨大努力,如今已有许多药物分子可用于应对医疗保健系统的各种挑战。不幸的是,这些药物中有一半以上属于BCS(生物药剂学分类系统)II/IV类,或者由于临床应用有限而从研发流程中淘汰。纳米技术方法带来了很大希望,人们发现脂质制剂适用于此类药物的递送。基于纳米乳剂的凝胶,即不同纳米脂质制剂中的纳米乳凝胶,已被发现是一种通过局部途径成功进行药物递送的合适方法。在过去几年中,许多草药和合成活性药物成分(API)已被专利化为用于各种治疗活动的纳米级乳化凝胶。
纳米乳凝胶基本上是一种基于乳剂的局部凝胶制剂,其中纳米级乳剂小球可借助高能或低能方法制备,然后通过添加合适的胶凝剂进一步转化为纳米乳凝胶。纳米乳凝胶的制备需要使用各种天然、合成和半合成性质的聚合物材料、表面活性剂和脂肪物质,小球尺寸范围为5至500纳米。
纳米乳凝胶可通过局部途径应用于各种急性和慢性疾病。
许多最近获批药物的纳米乳凝胶制剂已在医疗保健的不同领域成功使用,与其他给药途径相比,重新定义了局部给药途径的重要性。然而,随着给药系统当前状态的各种改进,此类制剂中所用材料的毒理学研究需要考虑安全因素。